TF and hepatocellular carcinoma: In this study, a TF-mediated liposomal drug delivery system was designed to slow down its release in vivo, as well as increase its targeting ability in vivo and in vitro, thereby reducing the drug’s toxicity, while enhancing its effects against HCC.